Lyell Immunopharma, Inc.
ronde-cel
large B-cell lymphoma (LBCL)
Countdown
542days
Phase 3 readout · ~ Dec 31, 2027 estimated
What's at stake
Phase 3 trial results for ronde-cel in large B-cell lymphoma (LBCL) are due ~ Dec 31, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“pivotal data expected in mid-2027 with submission of a Biologics License Application (BLA) to the FDA expected to follow in 2027.”